» Articles » PMID: 37231665

Genetic, Vascular and Amyloid Components of Cerebral Blood Flow in a Preclinical Population

Abstract

Aging-related cognitive decline can be accelerated by a combination of genetic factors, cardiovascular and cerebrovascular dysfunction, and amyloid-β burden. Whereas cerebral blood flow (CBF) has been studied as a potential early biomarker of cognitive decline, its normal variability in healthy elderly is less known. In this study, we investigated the contribution of genetic, vascular, and amyloid-β components of CBF in a cognitively unimpaired (CU) population of monozygotic older twins. We included 134 participants who underwent arterial spin labeling (ASL) MRI and [F]flutemetamol amyloid-PET imaging at baseline and after a four-year follow-up. Generalized estimating equations were used to investigate the associations of amyloid burden and white matter hyperintensities with CBF. We showed that, in CU individuals, CBF: 1) has a genetic component, as within-pair similarities in CBF values were moderate and significant (ICC > 0.40); 2) is negatively associated with cerebrovascular damage; and 3) is positively associated with the interaction between cardiovascular risk scores and early amyloid-β burden, which may reflect a vascular compensatory response of CBF to early amyloid-β accumulation. These findings encourage future studies to account for multiple interactions with CBF in disease trajectory analyses.

Citing Articles

Blood biomarkers for vascular cognitive impairment based on neuronal function: a systematic review and meta-analysis.

Huang W, Liao L, Liu Q, Ma R, He X, Du X Front Neurol. 2025; 16:1496711.

PMID: 39990267 PMC: 11842260. DOI: 10.3389/fneur.2025.1496711.


Regional cerebral blood flow reflects both neurodegeneration and microvascular integrity across the Alzheimer's continuum.

Taghvaei M, Dolui S, Sadaghiani S, Shakibajahromi B, Brown C, Khandelwal P Alzheimers Dement. 2024; 21(1):e14382.

PMID: 39625074 PMC: 11772719. DOI: 10.1002/alz.14382.


Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer's disease preclinical phase evaluated by dual-phase F-florbetaben positron emission tomography.

Kim G, Kim B, Yoon H, Jeong J Sci Rep. 2024; 14(1):18480.

PMID: 39122860 PMC: 11315901. DOI: 10.1038/s41598-024-68916-4.


Time-encoded ASL reveals lower cerebral blood flow in the early AD continuum.

Falcon C, Montesinos P, Vaclavu L, Kassinopoulos M, Minguillon C, Fauria K Alzheimers Dement. 2024; 20(8):5183-5197.

PMID: 38958557 PMC: 11350027. DOI: 10.1002/alz.14059.


Vascular contributions to cognitive decline: Beyond amyloid and tau in the Harvard Aging Brain Study.

Shirzadi Z, Boyle R, Yau W, Coughlan G, Fu J, Properzi M J Cereb Blood Flow Metab. 2024; 44(8):1319-1328.

PMID: 38452039 PMC: 11342726. DOI: 10.1177/0271678X241237624.

References
1.
Mattsson N, Tosun D, Insel P, Simonson A, Jack Jr C, Beckett L . Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain. 2014; 137(Pt 5):1550-61. PMC: 3999717. DOI: 10.1093/brain/awu043. View

2.
Preibisch C, Sorg C, Forschler A, Grimmer T, Sax I, Wohlschlager A . Age-related cerebral perfusion changes in the parietal and temporal lobes measured by pulsed arterial spin labeling. J Magn Reson Imaging. 2011; 34(6):1295-302. DOI: 10.1002/jmri.22788. View

3.
Kester M, Goos J, Teunissen C, Benedictus M, Bouwman F, Wattjes M . Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol. 2014; 71(7):855-62. DOI: 10.1001/jamaneurol.2014.754. View

4.
Hammers A, Koepp M, Free S, Brett M, Richardson M, Labbe C . Implementation and application of a brain template for multiple volumes of interest. Hum Brain Mapp. 2002; 15(3):165-74. PMC: 6871918. DOI: 10.1002/hbm.10016. View

5.
Tanzi R . The genetics of Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 2(10). PMC: 3475404. DOI: 10.1101/cshperspect.a006296. View